Nov 07, 2024 / 01:00PM GMT
Jeffrey Simmons - Elanco Animal Health Inc - President, Chief Executive Officer, Director
(Audio in progress)
2024 our consistent strategy focused on growth, innovation and cash is paying off with innovative new products driving growth, enabling improved cash flow. Beginning on Slide 4, we achieved key milestones dancing our innovation portfolio and productivity strategy. Third quarter revenue growth, excluding the impact of our aqua divestiture, was led by our U.S. farm and international pet health businesses. For Elanco overall we expect organic growth to accelerate sequentially in the fourth quarter and into next year.
Since our last earnings call, we achieved several milestones for key potential blockbuster products as we now shift from regulatory into commercial launch mode. On a pet outside, we received US, FDA approval for both Centralia and Credelio Quattro positively differentiated products expected to be meaningful competitors in the two largest markets in pet health. On the farm side, both there so the first on-farm feeding into dairy cows to fly, we'll is beginning to move as
Q3 2024 Elanco Animal Health Inc Earnings Call Transcript
Nov 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers